SLC5A2 and metabolic dysfunction-associated steatotic liver disease: In line with this, the role of a novel oral hypoglycemic agent called sodium–glucose cotransporter 2 (SGLT-2) inhibitor on the treatment of NAFLD has recently been investigated in various animal studies done on rodents models8–10 and human clinical trials11,12, with potential positive effects.